Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

How patient engagement improves outcomes in chronic illness

By Chloe Patel

- PMLiVE

Generative AI, storytelling and patient inclusion: key publications trends in 2024

By Teal Brechtel and Jennifer Gillman

Amiculum

- PMLiVE

FDA approves Samsung Bioepis’ Soliris biosimilar Epysqli for rare blood disorders

Epysqli has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

MHRA approves first generic raltegravir medicines to treat HIV in adults and children

More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

- PMLiVE

Paratek announces positive late-stage results for Nuzyra in bacterial pneumonia

The condition, caused by various bacteria, affects more than 900,000 people in the US every year

- PMLiVE

Q&A with Springer Nature’s Leslie Lansman

Ethical content sharing and the benefits of the CLA Pharmaceutical Licence

- PMLiVE

Missed Origins’ Webinar? Watch How Patient Experience Data is Changing Pharma!

We are thrilled to announce that the recording of our recent webinar, "Patient Data: From data to decisions, maximising the impact of patience experience data in pharma" is now available...

Origins – The Patient Focused Specialists

- PMLiVE

New report now available: Integrating ‘patient first’ into medicine development

A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map...

Cuttsy + Cuttsy

- PMLiVE

J&J’s Tecvayli recommended by NICE to treat relapsed and refractory multiple myeloma

Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK

- PMLiVE

Boehringer Ingelheim and Brainomix enter fibrosing lung disease partnership

Pulmonary fibrosis, a chronic lung condition, affects up to 20 out of every 100,000 people worldwide

- PMLiVE

LEO Pharma’s delgocitinib cream shows promise in phase 3 chronic hand eczema trials

About 70% of patients with severe cases of the condition report problems performing everyday activities

- PMLiVE

The omnichannel wonderland of opportunities

Picking your omnichannel direction requires a disciplined, scientific approach

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links